Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study.

ABSTRACT:

Background

Radiotherapy (RT) provides meaningful local control for hepatocellular carcinoma (HCC) but is limited by radio-resistance. Preclinical and clinical data suggest that adding programmed death receptor-1 (PD-1) blockade may enhance radiosensitivity in various malignancies. We compared outcomes of stereotactic body radiotherapy (SBRT) plus PD-1 inhibitors vs SBRT alone in unresectable HCC.

Methods

We retrospectively analyzed consecutive patients treated with SBRT (January 2019-December 2024) from 3 centers. Key exclusions removed confounding from recent systemic/locoregional therapies. Propensity score matching (PSM, 1:1) balanced demographics, liver function, tumor characteristics, and prior therapy. Tumor responses were assessed by RECIST 1.1, while survival was est

SUBMITTER: Wei X 

PROVIDER: S-EPMC12923107 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature